These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12194173)

  • 21. Allowing central fill pharmacies and retail pharmacies to fill prescriptions for controlled substances on behalf of retail pharmacies. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37405-11. PubMed ID: 12836645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medicare program; interest charges on overpayments and underpayments to providers and suppliers of services--HCFA. Final rule; correction.
    Fed Regist; 1984 Nov; 49(217):44472. PubMed ID: 10299729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicaid program; Medicaid managed care. Withdrawal of final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2002 Jun; 67(115):40987-40989. PubMed ID: 12068900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Schedules of controlled substances; placement of 2,5-dimethoxy-4-(n)-propylthiophenethylamine and N-benzylpiperazine into Schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Mar; 69(53):12794-7. PubMed ID: 15029891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Access charges; MTS and WATS market structure--Federal Communications Commission. Final rule.
    Fed Regist; 1983 Mar; 48(49):10319-69. PubMed ID: 10259818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Nov; 71(218):66108-9. PubMed ID: 17099971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clarification of registration requirements for individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2006 Dec; 71(231):69478-80. PubMed ID: 17171847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinton and appeals court signal death knell for Title X gag rule.
    Wash Memo Alan Guttmacher Inst; 1992 Nov; (17):1-2. PubMed ID: 12344619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prescription Drug Marketing Act Pedigree Requirements; effective date and compliance policy guide; request for comment. Final rule; announcement of effective date; notice of availability; request for comment.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(114):34249-51. PubMed ID: 16795943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schedules of controlled substances: placement of pregabalin into schedule V. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2005 Jul; 70(144):43633-5. PubMed ID: 16050051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 May; 68(84):23195-206. PubMed ID: 12725239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Schedules of controlled substances: placement of Zopiclone into schedule IV. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2005 Apr; 70(63):16935-7. PubMed ID: 15806735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Removal of thresholds for the List I chemicals pseudoephedrine and phenylpropanolamine. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2010 Jul; 75(129):38915-22. PubMed ID: 20608288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schedules of controlled substances: placement of lisdexamfetamine into schedule II. Final rule.
    Drug Enforcement Administration, Department of Justice
    Fed Regist; 2007 May; 72(85):24532-4. PubMed ID: 17520775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
    Food and Drug Administration. HHS
    Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schedules of controlled substances: placement of lacosamide into schedule V. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2009 May; 74(97):23789-90. PubMed ID: 19507328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DEA issues proposed rule on e-prescribing.
    Ball FR
    J Med Pract Manage; 2009; 24(4):243. PubMed ID: 19288650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exempt chemical mixtures containing gamma-butyrolactone. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Jun; 75(124):37301-7. PubMed ID: 20608286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Interim rule with request for comments.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Apr; 72(77):20039-47. PubMed ID: 17520757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.